



## Artery Research

ISSN (Online): 1876-4401

ISSN (Print): 1872-9312

Journal Home Page: <https://www.atlantis-press.com/journals/artres>

---

### **P3.22: CHROMOSOME 9P21 LOCUS AND CORONARY ARTERY DISEASE – COLLABORATIVE META-ANALYSIS ON ANGIOGRAPHIC BURDEN AND MOLECULAR FUNCTION ANALYSIS**

K. Chan, A. Motterle, R.S. Patel, X. Pu, S. Ye

**To cite this article:** K. Chan, A. Motterle, R.S. Patel, X. Pu, S. Ye (2013) P3.22: CHROMOSOME 9P21 LOCUS AND CORONARY ARTERY DISEASE – COLLABORATIVE META-ANALYSIS ON ANGIOGRAPHIC BURDEN AND MOLECULAR FUNCTION ANALYSIS, Artery Research 7:3\_4, 132–132, DOI: <https://doi.org/10.1016/j.artres.2013.10.109>

**To link to this article:** <https://doi.org/10.1016/j.artres.2013.10.109>

Published online: 14 December 2019

<sup>1</sup>University of Padova, Padova, Italy

<sup>2</sup>Town Hospital, San Daniele del Friuli, Italy

<sup>3</sup>Town Hospital, Vittorio Veneto, Italy

<sup>4</sup>Town Hospital, Cremona, Italy

<sup>5</sup>Town Hospital, Trento, Italy

**Objective:** The aim of the study was to examine the relationship between AASI and age in a cohort of stage I hypertensives < 50 years of age and to investigate its predictive capacity for future established hypertension.

**Methods:** We studied 1157 subjects from the HARVEST study (mean follow-up 5.9 years). AASI and 24-h pulse pressure (PP) were calculated from 24-h ambulatory recordings. The predictive value of AASI for incident hypertension was evaluated with Cox regression analysis adjusting for age, sex, mean 24-h blood pressure (BP).

**Results:** Baseline office BP was  $145.5 \pm 10.4/93.6 \pm 5.6$  mmHg, 24-h PP was  $49.6 \pm 11.2$  mmHg, AASI was  $0.56 \pm 0.2$ . AASI was correlated with 24-h PP ( $r=0.41$ ,  $p<0.0001$ ), and showed a U-shaped correlation with age. In our population age was inversely correlated with 24-h PP ( $r=-0.32$ ,  $p<0.0001$ ). The highest sex-adjusted AASI values were found in the two bottom and the top age deciles (mean $\pm$ SEM,  $0.62 \pm 0.02$ ,  $0.61 \pm 0.02$ , and  $0.60 \pm 0.02$ , respectively). During follow-up 55.7% of the subjects developed established hypertension needing pharmacological treatment. In a multivariate Cox analysis, AASI showed a negative predictive value for the development of future hypertension ( $p<0.001$ ). Participants in the middle AASI tertile (H.R. and 95%CI: 0.81, 0.67-0.97,  $p=0.03$ ) and top tertile (0.71, 0.57-0.87,  $p=0.001$ ) had a lower risk of developing hypertension compared to subjects in the bottom tertile.

**Conclusions:** AASI shows a U-shaped relationship with age in a population of young-to-middle-age hypertensives and it may be even a predictor of better outcome. So, the clinical significance of AASI in hypertension appears to be heavily dependent on age.

### P3.21

#### CENTRAL HEMODYNAMICS PARAMETERS IN BLACK HYPERTENSIVE PATIENTS BORN AND LIVING IN SUB-SAHARAN AFRICA

M. K. Kamdem <sup>1</sup>, E. A. Birinus <sup>2</sup>, D. Lemougoum <sup>1</sup>, B. C. Ansiuba <sup>2</sup>, J. Kaptue <sup>1</sup>, J. Staessen <sup>3,4</sup>, M'buyamba Rene <sup>3,5</sup>, A. Odili <sup>6</sup>

<sup>1</sup>Douala Cardiovascular Research Institute, Douala School of Medicine, Douala, Cameroon

<sup>2</sup>Department of Medicine, College of Medicine, University of Nigeria Teaching Hospital, Enugu, Nigeria

<sup>3</sup>Studies Coordinating Centre, Division of Hypertension and Cardiovascular Rehabilitation, Department of Cardiovascular Di, leuven, Belgium

<sup>4</sup>Department of Epidemiology, Maastricht University, Maastricht, Netherlands

<sup>5</sup>Hypertension Unit, Department of Internal Medicine, University of Kinshasa Hospital, Kinshasa, The Democratic Republic of, kinshasa, Democratic Republic of the Congo

<sup>6</sup>Department of Internal Medicine, College of Health Science, University of Abuja, Abuja, Nigeria

**Background:** Few studies assessed arterial stiffness in Black hypertensive patients Born and living in sub-Saharan Africa, where cardiovascular disease reaches epidemic proportions.

**Methods:** The Newer versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trial had recruited native African patients to compare the efficacy of various Antihypertensive drugs given once daily as single-pill combinations. Two centers engaged in Pulse wave analysis and measured carotid femoral pulse wave velocity (PWV). Statistical Methods included single and multiple linear regressions.

**Results:** Of 172 patients screened, 116 entered the ancillary study on central hemodynamics (51.3% women; mean age 52.7 years; untreated blood pressure 147.6/87.1 mm Hg), the augmentation indexes were higher ( $p<0.0001$ ) in women than men, both peripherally (pAI, 11.1 vs.10.6%) and centrally (cAI, 39.0 vs. 28.0%). PWV (8.91 m/s) and central pulse pressure (cPP, 48.7 mm Hg) were similar ( $p>0.844$ ) in both sexes. pAI and cAI increased with female sex and mean arterial pressure, but decreased with heart rate and body mass index. cPP increased with age and mean arterial pressure. PWV increased with age and mean arterial pressure. Patients with measurements above the age-specific thresholds determined in healthy Black South Africans amounted to 0 for cAI, 1 (1.2%) for cPP, and 11 (18.3%) for PWV.

**Conclusion:** NOAAH patients have measures of arterial stiffness similar to those of a healthy Black reference population with determinants as reported in the literature. Our observations Highlight the potential for the prevention

of irreversible arterial damage by timely treating Sub-Saharan hypertensive patients to target blood pressure levels.

### P3.22

#### CHROMOSOME 9P21 LOCUS AND CORONARY ARTERY DISEASE – COLLABORATIVE META-ANALYSIS ON ANGIOGRAPHIC BURDEN AND MOLECULAR FUNCTION ANALYSIS

K. Chan <sup>1</sup>, A. Motterle <sup>1</sup>, R. S. Patel <sup>1,2</sup>, X. Pu <sup>1</sup>, S. Ye <sup>1</sup>

<sup>1</sup>William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University London, London, United Kingdom

<sup>2</sup>Department of Medicine, Emory University School of Medicine, Atlanta, United States of America

**Objective:** Chromosome 9p21 variants showed robust association with coronary heart disease in genome-wide association studies, but questions remain on the mechanism. We investigated the relationship of 9p21 locus with (1) angiographic coronary artery disease (CAD) burden and progression to myocardial infarction (MI); and (2) biological function of vascular smooth muscle cell (VSMC).

**Methods and results:** We established a collaboration of 21 studies (33,673 patients) with information on both CAD and MI status along with 9p21 genotype. We first confirmed an association between 9p21 and CAD using angiographic ally defined cases and controls (pooled odds ratio (OR)=1.31 (95% CI 1.20-1.43) per copy of risk allele). Among subjects with angiographic CAD, random-effects model identified an association with multi-vessel CAD, compared to those with single-vessel disease (OR=1.10 (95% CI 1.04-1.17)). However, there was no significant association between 9p21 and prevalent MI when both cases and controls had underlying CAD (OR=0.99 (95% CI 0.95-1.03)). Immunohistochemical staining of human atherosclerotic plaque showed co-localization of VSMC with the cell-cycle regulator proteins p16<sup>INK4a</sup>, p14<sup>ARF</sup> and p15<sup>INK4b</sup>, which are encoded by the genes *CDKN2A* and *CDKN2B* genomically located nearby the 9p21 locus. The 9p21 risk genotype confers reduced p15<sup>INK4b</sup> levels ( $p=3.7 \times 10^{-2}$ ) and higher VSMC content ( $p=5.6 \times 10^{-4}$ ) in the plaques. We further examined the influence of 9p21 genotype on primary cultures of VSMC isolated from human umbilical cord. The risk genotype was associated with reduced expression of p16<sup>INK4a</sup>, p15<sup>INK4b</sup> ( $p=1.2 \times 10^{-5}$ ,  $1.4 \times 10^{-2}$ ), and increased VSMC proliferation ( $p=1.6 \times 10^{-2}$ ).

**Conclusions:** The 9p21 locus primarily mediates an atherosclerotic phenotype, by influencing *CDKN2A/CDKN2B* expression and hence VSMC proliferation.

### P3.23

#### URINARY ALBUMIN EXCRETION FROM SPOT URINE SAMPLES PREDICT ALL-CAUSE AND STROKE MORTALITY IN AFRICANS

R. Schutte <sup>1</sup>, A. E. Schutte <sup>1</sup>, H. W. Huisman <sup>1</sup>, J. M. van Rooyen <sup>1</sup>, C. M. T. Fourie <sup>1</sup>, R. Kruger <sup>1</sup>, C. M. C. Mels <sup>1</sup>, L. Malan <sup>1</sup>, N. T. Malan <sup>1</sup>, W. Smith <sup>1</sup>, M. Greeff <sup>2</sup>, A. Kruger <sup>2</sup>

<sup>1</sup>Hypertension in Africa Research Team, North-West University, Potchefstroom, South Africa

<sup>2</sup>African Unit for Transdisciplinary Health Research, North-West University, Potchefstroom, South Africa

Twenty-four hour urinary albumin excretion reflects general endothelial damage, relates to arterial stiffness, and predicts adverse health outcomes. Albumin determined from easily collected spot urine samples is also predictive. No prognostic evidence for albumin excretion from any means of urine collection exists for Africans. We followed health outcomes in 1061 randomly selected non-diabetic, HIV negative Africans (mean age: 51.5 years; 62.0% women). We determined the baseline urinary albumin-to-creatinine ratio from spot urine samples. Over a median follow-up of 4.52 years, 132 deaths occurred of which 47 were cardiovascular-related. The urinary albumin-to-creatinine ratio averaged 0.68 (5th to 95th percentile interval; 0.13, 4.54 mg/mmol). In multivariable-adjusted analyses, albumin excretion predicted all-cause mortality (hazard ratio, 1.26; 95% confidence interval, 1.07, 1.48;  $P=0.006$ ), and a tendency existed for cardiovascular (1.26; 0.97, 1.63;  $P=0.087$ ) mortality, which seemed driven by stroke (1.72; 1.17, 2.54;  $P=0.006$ ) and not cardiac mortality (0.67; 0.41, 1.07;  $P=0.094$ ). The predictive value remained in 528 hypertensives for both all-cause (1.38; 1.13, 1.69;  $P=0.001$ ) and cardiovascular mortality (1.45; 1.07, 1.96;  $P=0.017$ ), but again driven by stroke. Our findings remained significant after excluding participants with macroalbuminuria and those on anti-hypertensive treatment. In conclusion, in non-diabetic HIV-negative